

FAX FORM TO: 1.877.597.3070 | PHONE: 1.800.473.3516 | EMAIL: specialty@wellpartner.com

Complete the following or include demographic sheet.

1. PATIENT INFORMATION			2. PRESCRIBER INFORMATION		
Name:			Name:		
Address:			DEA#: NPI#:	State Lic. #:	
City, State, ZIP:			Group or Hospital:		
Primary Phone: DOB: / /			Address:		
Alternate Phone: Gender:			City, State, Zip:		
Email:			Phone:	Fax:	
Primary Language: Last Four of SSN:		Last Four of SSN:	Contact Person:	Phone:	
3. INSURAN	ICE INFORMATION	Fax copy of pres a	cription and insurance cards with this fo	orm, if available (front a	nd back)
Primary Insurance Company Name:			Secondary Insurance Company Name:		
Primary Cardholder Name:			Secondary Cardholder Name:		
Relationship: O Self O Spouse/Partner O Child/Dependent			Relationship: Self Spouse/Partner Child/Dependent		
Phone:	Membe	r ID: Group #:	Phone: Membe	er ID: Group #	<i>‡</i> :
4. DIAGNOS	SIS AND CLINICAL INFO	DRMATION			
Needs by Date	e: / /	Ship to: Patient	t Office Other:		
Date of Diagno	osis: / /	Type of therapy: O Nev	w Continuing Restart		
○ D59.5 Paroxysmal nocturnal hemoglobinuria (PNH) Has patient received me lif no, reason: ○ D59.3 Hemolytic-uremic syndrome Infusion appointment dates			ningococcal vaccination? Yes No		
Other: Allergies:					
Height (in/cm): Weight (lb/kg): Current Medica					
5. PRESCRIF	PTION INFORMATION				
Medication	Dose/Strength	Directions		Quantity	Refills
○ Soliris	300 mg/30 ml vial (10 mg/ml)	for 4 weeks Dose titration to maintenance - IV infusion every 2 weeks starti	nister 600 mg via IV infusion every 7 days - Month 2: Administer 900 mg via ing on week 5 er 900 mg vial IV infusion every 2 weeks	4-week supply 12-week supply	
		For treatment of aHUS - 18 years or	r older	4-week supply	
		for 4 weeks	ister 900 mg via IV infusion every 7 days	12-week supply	
		Dose titration to maintenance - IV infusion every 2 weeks starti	ing on week 5		
		Maintenance dosing: Administe Other:	er 1200 mg vial IV infusion every 2 weeks		
ncillary supplies	s and kits will be provided	as needed for administration.			
6. PRESCRII	BER SIGNATURE				
(/ /	Х		/ /
	TEN	DATE	PRODUCT SUBSTITUTION PERMITTED		DAT

IMPORTANT NOTICE: This facsimile transmission is intended to be delivered only to the named addressee and may contain material that is confidential, privileged, proprietary or exempt from disclosure under applicable law.

If it is received by anyone other than the named addressee, the recipient should immediately notify the sender at the address or telephone number set forth herein and obtain instructions as to disposal of the transmitted material. In no event should such material be read or retained by anyone other than the named addressee, except by express authority of the sender to the named addressee.